Spectral Medical (EDT) Q4 2024 earnings summary

Executive summary

• Focused on developing and commercializing PMX for septic shock, with ongoing legacy reagent sales.

• Revenue increased to $2.29M in 2024 from $1.60M in 2023, but net loss remained high at $15.4M.

• Significant funding needs and material uncertainty about ability to continue as a going concern.

• Multiple financings completed, including convertible notes and private placements.

Financial highlights

• Revenue: $2.29M in 2024, up from $1.60M in 2023.

• Net loss: $15.4M in 2024, similar to $15.7M in 2023.

• Cash at year-end: $3.0M, up slightly from $3.0M in 2023.

• Operating cash outflow: $8.8M in 2024, improved from $10.7M in 2023.

• Notes payable increased to $14.4M from $7.9M; derivative liability rose to $9.7M from $6.3M.

Outlook and guidance

• Continued focus on FDA approval and commercialization of PMX.

• Additional funding required for operations and regulatory programs; no assurance of success.

• Recent contract amendments extend distribution rights and clinical study timelines.